NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.66 -0.34 (-0.43%) GOLD FUTURES
2,309.50 -1.50 (-0.06%) DOW
38,025.04 +121.75 (+0.32%) Bitcoin GBP
47,216.05 +1,422.77 (+3.11%)
JW (Cayman) Therapeutics Co. Ltd (JNY.F)
| Previous close | 0.2040 |
| Open | 0.2120 |
| Bid | 0.2160 x N/A |
| Ask | 0.2380 x N/A |
| Day's range | 0.2100 - 0.2160 |
| 52-week range | 0.1800 - 0.3295 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 94.109M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireJW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treatment of adult patients with relapsed o
PR NewswireJW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development and commercialization of a chimeric antigen receptor (CAR) T-cell therapy product for autoimmune diseases (AID program) in Greater China.
